CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of
cancer metabolism and inborn errors of metabolism, today announced that
David Schenkein, M.D., chief executive officer, is scheduled to present
at the 32nd Annual J.P. Morgan Healthcare Conference onMonday, January 13, 2014 at 3:00p.m. PST in San Francisco.
A live, listen-only webcast of the presentation can be accessed by
visiting the investors section of the Agios website at
investor.agios.com. A replay of the webcast will be available shortly
after the conclusion of the presentation and archived on the company's
website for two weeks following the presentation.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and inborn errors of metabolism, or IEMs, which
are rare genetic metabolic diseases, through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs in
clinical and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our knowledge of
metabolism, biology and genomics. For more information, please visit our
website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding Agios' expectations
and beliefs about its plans and strategies. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual events
or results to differ materially from Agios' current expectations and
beliefs, including risks and uncertainties relating to: Agios' ability
to successfully commence and complete necessary preclinical and clinical
development of its product candidates; Agios' results of clinical trials
and preclinical studies, including subsequent analysis of existing data
and new data received from ongoing and future studies; Agios' ability to
maintain its collaboration with third parties on acceptable terms; the
content and timing of decisions made by the U.S. FDA and other
regulatory authorities, investigational review boards at clinical trial
sites and publication review bodies; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain, maintain
and enforce patent and other intellectual property protection for any
product candidates it is developing; Agios' ability to obtain the
substantial additional capital required to execute its plans and
strategies; and general economic and market conditions. These and other
risks are described in greater detail in filings that Agios makes with
the SEC from time to time including risks described under the caption
"Risk Factors" included in Agios' Quarterly Report on Form 10-Q for the
quarter ended September 30, 2013. Any forward-looking statements
contained in this press release speak only as of the date hereof, and
Agios expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events or
Source: Agios Pharmaceuticals, Inc.